title: Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
abstract: Nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), leads to fibrosis and potentially cirrhosis, liver failure, and hepatocellular carcinoma, and is one of the most common causes of liver disease worldwide. NAFLD has also been implicated in other medical conditions such as insulin resistance, obesity, metabolic syndrome, hyperlipemia, hypertension, cardiovascular disease, and diabetes. Continuous hyperglycemia has been implicated in the pathogenesis of diabetic micro- and macro-vascular complications via various metabolic pathways, and numerous hyperglycemia-induced metabolic and hemodynamic conditions exist, including the increased generation of various types of advanced glycation end-products (AGEs). We recently demonstrated that glyceraldehyde-derived AGEs (Glycer-AGEs), the predominant components of toxic AGEs (TAGE), played an important role in the pathogenesis of angiopathy in diabetic patients. Moreover, a growing body of evidence suggests that the interaction between TAGE and the receptor for AGEs may alter intracellular signaling, gene expression, and the release of pro-inflammatory molecules and also elicits the generation of oxidative stress in numerous types of cells including hepatocytes and hepatic stellate cells. Serum levels of TAGE were significantly higher in NASH patients than in those with simple steatosis and healthy controls. Moreover, serum levels of TAGE inversely correlated with adiponectin (adiponectin is produced by adipose tissue and is an anti-inflammatory adipokine that can increase insulin sensitivity). Furthermore, immunohistochemical staining of TAGE showed intense staining in the livers of patients with NASH. Serum levels of TAGE may be a useful biomarker for discriminating NASH from simple steatosis. The administration of atorvastatin (10 mg daily) for 12 months significantly improved NASH-related metabolic parameters and significantly decreased serum levels of TAGE. The steatosis grade and NAFLD activity score were also significantly improved. These results demonstrated that atorvastatin decreased the serum levels of TAGE in NASH patients with dyslipidemia and suggest the usefulness of TAGE as a biomarker for the attenuation of NASH. Serum levels of TAGE were significantly higher in non-B or non-C hepatocellular carcinoma (NBNC-HCC) patients than in NASH subjects without HCC or control subjects. TAGE may be involved in the pathogenesis of NBNC-HCC, and could, therefore, be a biomarker that could discriminate NBNC-HCC from NASH. We propose that serum levels of TAGE are promising novel targets for the diagnosis of and therapeutic interventions against NASH.
authors.affiliation: Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan. Electronic address: takeuchi@kanazawa-med.ac.jp.
authors.forename: M
authors.initials: M
authors.lastname: Takeuchi
authors.affiliation: Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Sakasai-Sakai
authors.affiliation: Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Takata
authors.affiliation: Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.affiliation: Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, Hiroshima, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Takino
authors.affiliation: Department of Hepatology, Kanazawa Medical University, Ishikawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Tsutsumi
authors.affiliation: Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hyogo
authors.affiliation: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Fukuoka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yamagishi
mesh_terms: D015415:Biomarkers / Q000097:blood*; D018450:Disease Progression; D017127:Glycation End Products, Advanced / Q000097:blood* / Q000633:toxicity; D006801:Humans; D008954:Models, Biological; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood* / Q000209:etiology*
chemical_list: D015415:Biomarkers; D017127:Glycation End Products, Advanced